Estrella Immunopharma, Inc.

NasdaqCM:ESLA Stock Report

Market Cap: US$48.6m

Estrella Immunopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Cheng Liu

Chief executive officer

US$251.0k

Total compensation

CEO salary percentage100.00%
CEO tenureno data
CEO ownership0.7%
Management average tenureno data
Board average tenure2.8yrs

Recent management updates

Recent updates

Analysis Article • Nov 30

Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 17

Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Invest In Growth?

NasdaqCM:ESLA 1 Year Share Price vs Fair Value Explore Estrella Immunopharma's Fair Values from the Community and...
Analysis Article • Oct 09

Companies Like Estrella Immunopharma (NASDAQ:ESLA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Cheng Liu's remuneration changed compared to Estrella Immunopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$13m

Dec 31 2025US$251kUS$251k

-US$13m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$895kUS$125k

-US$9m

Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023n/an/a

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022n/an/a

-US$6m

Sep 30 2022n/an/a

-US$4m

Jun 30 2022US$590kn/a

-US$1m

Compensation vs Market: Cheng's total compensation ($USD250.96K) is below average for companies of similar size in the US market ($USD642.98K).

Compensation vs Earnings: Cheng's compensation has been consistent with company performance over the past year.

CEO

Cheng Liu (59 yo)

no data
Tenure
US$250,962
Compensation

Dr. Cheng Liu, PhD, is Founder of Eureka Therapeutics, Inc. and has been its Chief Executive Officer and President and Member of Board of Directors since May 2006. He is Chairman at JW (Cayman) Therapeutic...

Board Members

NamePositionTenureCompensationOwnership
Cheng Liu
CEO, President & Directorno dataUS$250.96k0.69%
$ 336.1k
David Scheinberg
Member of Scientific Advisory Boardno datano datano data
Xuejun Wu
Independent Director2.8yrsUS$20.00kno data
Randy Wayne Schekman
Member of Scientific Advisory Boardno datano datano data
Hong Zhang
Chairman1.8yrsUS$250.00k0.56%
$ 271.7k
Stephan Grupp
Member of Scientific Advisory Boardno datano datano data
Pei Xu
Independent Director2.8yrsUS$20.00kno data
Marsha Roberts
Independent Directorno dataUS$20.00kno data
Fan Wu
Independent Director2.8yrsUS$20.00kno data
Dengyao Jia
Directorless than a yearno datano data
2.8yrs
Average Tenure
55yo
Average Age

Experienced Board: ESLA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 04:02
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Estrella Immunopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BautzZacks Small-Cap Research